NewAmsterdam Pharma Schedules R&D Day for June 2025

An announcement from NewAmsterdam Pharma Company ( (NAMS) ) is now available.

NewAmsterdam Pharma Company announced a Research & Development Day event scheduled for June 11, 2025, in New York City, aimed at analysts and investors. The event will be webcast live, with a replay available for 30 days. The company has been active in clinical trials, with significant developments in its BROOKLYN, BROADWAY, and TANDEM Phase 3 studies, and has secured funding to support a potential U.S. commercial launch. The company’s product candidate, Obicetrapib, shows promise in addressing cardiometabolic diseases, and there are ongoing efforts to explore its therapeutic potential in Alzheimer’s disease and multi-infarct dementia.

The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

Spark’s Take on NAMS Stock

According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.

The stock’s score is primarily influenced by its financial performance challenges, with high R&D costs impacting profitability. The strong technical indicators suggest positive short-term momentum, but valuation concerns due to negative earnings weigh heavily.

To see Spark’s full report on NAMS stock, click here.

More about NewAmsterdam Pharma Company

NewAmsterdam Pharma Company N.V. operates in the pharmaceutical industry, focusing on the development of therapies for cardiometabolic diseases and Alzheimer’s disease. The company is engaged in clinical trials and product development, with a market focus on innovative treatments that address unmet medical needs.

Average Trading Volume: 909,801

Technical Sentiment Signal: Buy

Current Market Cap: $2.45B

See more data about NAMS stock on TipRanks’ Stock Analysis page.